Trial Profile
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Omeprazole (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Duodenal ulcer; Dyspepsia; Embolism and thrombosis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris; Zollinger-Ellison syndrome
- Focus Pharmacodynamics
- Sponsors Sanofi
- 25 Aug 2010 Trial phase changed from IV to I as reported by ClinicalTrials.gov.
- 29 May 2010 New trial record